- Conditions
- Myasthenia Gravis, Ocular
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 13,292
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Urinary Bladder, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- UGN-501
- Biological
- Lead sponsor
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more
- Conditions
- Breathing, Aging
- Interventions
- Breathing Room
- Other
- Lead sponsor
- University of Wisconsin, Milwaukee
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Melanoma, Carcinoma, Renal Cell
- Interventions
- rh IL-15
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- TN-201
- Genetic
- Lead sponsor
- Tenaya Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 10
- States / cities
- La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
- Conditions
- Obesity and Overweight
- Interventions
- NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide
- Drug
- Lead sponsor
- Biomed Industries, Inc.
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 5 more
- Conditions
- Brain Tumor, Metastatic Brain Tumor
- Interventions
- Resting-state functional connectivity MRI, Neurocognitive battery with quality-of-life assessment
- Diagnostic Test · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- VRC01, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more
- Conditions
- Microvessels, Carbohydrate Metabolism, Diabetes Mellitus, Type 2
- Interventions
- Not listed
- Lead sponsor
- University of Texas Rio Grande Valley
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Brownsville, Texas
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Personalized IBS Pain SM
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Farmington, Connecticut • Storrs, Connecticut
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 11
- States / cities
- Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
- Conditions
- Lupus Nephritis
- Interventions
- Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 17
- States / cities
- La Palma, California • San Leandro, California • Torrance, California + 13 more
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Interventions
- bevacizumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Endometrial Cancer, Urothelial Carcinoma (UC), Breast Cancer
- Interventions
- STRO-006, Pembrolizumab
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 3 more
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma, Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
- Interventions
- Alisertib
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Mount Holly, New Jersey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 8
- States / cities
- DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
- Conditions
- HIV Infections, Atherosclerosis
- Interventions
- Not listed
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hematological Malignancies, Graft-versus-Host Disease (GVHD)
- Interventions
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus, Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Brain Metastases, Adult
- Interventions
- Pre-operative Stereotactic Radiosurgery
- Other
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 13
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 10 more
- Conditions
- Leukaemia, Myelocytic, Acute
- Interventions
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Worcester, Massachusetts • Nashville, Tennessee
- Conditions
- Atopic Dermatitis
- Interventions
- CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 14
- States / cities
- Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
- Conditions
- No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
- Interventions
- Kaempferol
- Dietary Supplement
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Rancho Mirage, California + 15 more